Compass Therapeutics (CMPX) Cash from Investing Activities (2019 - 2026)

Compass Therapeutics (CMPX) has 8 years of Cash from Investing Activities data on file, last reported at $38.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 231.63% year-over-year to $38.4 million; the trailing twelve-month figure through Mar 2026 stood at -$66.5 million (down 206.41% YoY), and the FY2025 full-year result was -$93.3 million, down 299.49% from the prior year.
• Cash from Investing Activities improved to $38.4 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $38.4 million in Q1 2026 to a low of -$105.5 million in Q2 2022.
• A 5-year average of -$7.8 million and a median of $1.2 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 17089.09% in 2022 and jumped 2311.92% in 2023, its largest moves.
• Tracing CMPX's Cash from Investing Activities over 5 years: stood at -$46.6 million in 2022, then surged by 113.54% to $6.3 million in 2023, then jumped by 143.43% to $15.4 million in 2024, then tumbled by 121.98% to -$3.4 million in 2025, then jumped by 1237.63% to $38.4 million in 2026.
• Business Quant data shows CMPX's Cash from Investing Activities at $38.4 million in Q1 2026, -$3.4 million in Q4 2025, and -$95.2 million in Q3 2025.